| Clostridium difficile infection
Rebyota vs Vowst
Side-by-side clinical, coverage, and cost comparison for clostridium difficile infection.Deep comparison between: Rebyota vs Vowst with Prescriber.AI
AI compares prescribing info and payer-specific access barriers across 1,200+ formularies. Here's a preview of what prescribers are already asking.Safety signalsVowst has a higher rate of injection site reactions vs Rebyota based on FDA-approved prescribing information
Coverage gaps3 major payers require step therapy for Vowst but not Rebyota, including UnitedHealthcare
Sign up to reveal the full AI analysis
Category
Rebyota
Vowst
At A Glance
Rectal administration
Single dose
Live fecal microbiota
Oral
Once daily for 3 days
Fecal microbiota product
Indications
- Clostridium difficile infection
- Clostridium difficile infection
Dosing
Clostridium difficile infection A single 150 mL dose administered rectally 24 to 72 hours after the last dose of antibiotics for CDI.
Clostridium difficile infection 4 capsules orally once daily for 3 consecutive days, taken on an empty stomach prior to the first meal of the day; complete antibacterial treatment 2 to 4 days before initiating treatment; drink 296 mL (10 oz) magnesium citrate the day before and at least 8 hours prior to the first dose.
Contraindications
- History of severe allergic reaction (e.g. anaphylaxis) to any known product component
—
Adverse Reactions
Most common (>=3%) abdominal pain, diarrhea, abdominal distension, flatulence, nausea
Serious Serious adverse events reported in 10.1% of recipients within 6 months post-dose; none were considered related to REBYOTA.
Most common (>=5%) Abdominal distension, fatigue, constipation, chills, diarrhea
Serious No serious adverse events considered related to VOWST reported in clinical trials
Pharmacology
The mechanism of action of REBYOTA has not been established; it is a live fecal microbiota suspension administered rectally to individuals with recurrent Clostridioides difficile infection.
VOWST is a live biotherapeutic product consisting of bacterial spores derived from human fecal matter; its mechanism of action in preventing recurrent Clostridioides difficile infection has not been established.
Enter your patient's insuranceCheck specific coverage details for your patient.
Most Common Insurance
Anthem BCBS
Rebyota
- Covered on 5 commercial plans
- PA (10/12) · Step Therapy (0/12) · Qty limit (9/12)
Vowst
- Covered on 5 commercial plans
- PA (11/12) · Step Therapy (0/12) · Qty limit (9/12)
UnitedHealthcare
Rebyota
- Covered on 4 commercial plans
- PA (0/8) · Step Therapy (0/8) · Qty limit (0/8)
Vowst
- Covered on 4 commercial plans
- PA (6/8) · Step Therapy (4/8) · Qty limit (0/8)
Humana
Rebyota
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (0/3) · Qty limit (0/3)
Vowst
- Covered on 0 commercial plans
- PA (3/3) · Step Therapy (1/3) · Qty limit (1/3)
Coverage data sourced from MMIT. Updated monthly.
Savings
$100/fillfill
Rebyota Co-pay ProgramCommercial or private insurance
Medicare, Medicaid, VA, TRICARE
Cost estimate not availableAssistance Fund: Clostridium Difficile Associated Diarrhea
Commercial or private insurance
Medicare, Medicaid, VA, TRICARE
Let us handle your prior authsJust enter your patient's info and we'll:
- Verify eligibility with the payer.
- Pull the right PA forms directly from the payer.
- Submit, track & send live updates to your dashboard.
Free to start · HIPAA compliant
Next Steps for Your Patient
RebyotaView full Rebyota profile
Clinical data sourced from FDA-approved labeling. Coverage data via MMIT. Updated monthly.